Advanced Renal Cell Carcinoma Completed Phase 2 Trials for Axitinib (DB06626)

Also known as: Advanced Renal cell carcinoma

IndicationStatusPhase
DBCOND0032596 (Advanced Renal Cell Carcinoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01727336Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell CarcinomaTreatment